New insulin rival: can GZR4 beat current options for diabetes?
NCT ID NCT07165223
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new insulin drug, GZR4, against another insulin (Insulin Icodec) in 300 adults with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and causes fewer side effects like low blood sugar. Participants may also take other diabetes pills during the study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gan & Lee Pharmaceuticals Shandong Co., Ltd.
RECRUITINGLinyi, Shandong, 276000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?
- Could a peptide injection help rebuild Insulin-Making cells?